ROCKVILLE, Md. and BEIJING, July 22, 2020 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $1.90 per share. CASI has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock. The offering is expected to close on or about July 24, 2020, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $38.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI.

ROCKVILLE, Md. and BEIJING, July 21, 2020 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, CASI expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. There can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares of common stock in the offering will be sold by CASI.

CASI Pharmaceuticals, Inc. (纳斯达克股票代码：CASI) 是一家美国纳斯达克上市的医药公司。其使命是研发和加速创新疗法和药物在中国、美国及世界其他地区的上市进程。在中国北京设有全资子公司英创远达（北京）生物医药科技有限公司。CASI正式宣布与Black Belt Therapeutics Limited签署协议，CASI获得试验性新药TSK011010（抗CD-38单克隆抗体，以下简称抗CD-38单抗）全球独家权益。